Novartis AG

Open: 97.85 Close: 94.73 Change: -3.12

Our AI found unexpected things about Novartis AG.

The game is changing. There is a new strategy to evaluate Novartis AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, Ratings, company, value, Novartes, PCSK9, …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG has many opportunities for sustained growth in digital health, emerging markets, and gene therapy. BlackRock Inc., one of the largest asset management companies in the world, raised its stake in Novartes by 18.3% during the first quarter of this year. Bausch + Lomb confirms it is buying Novarte dry-eye treatment Xiidra from Novartesa.

Today's News

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. Analyst Ratings Sell Under Hold Over Buy number of Ratings 22 full Ratings. Novartis: Ultibro Breezhaler Superior to Seretide In Reducing COPD Exacerbations. Market capitalization represents a companys total value based on its current stock price and outstanding shares. Novartis AG has many opportunities for sustained growth in digital health, emerging markets, and gene therapy. BlackRock Inc., one of the largest asset management companies in the world, raised its stake in Novartes by 18.3% during the first quarter of this year. Novartis Pharmaceuticals Senior IT Specialist Marketing Automation, Innovative Medicines in Barcelona Gran Vía, Spain. Novartis AG has identified diaminocyclopentylpyridine derivatives acting as proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors. PCSK9 inhibitors are reported to be useful for the treatment of hypercholesterolemia, hyperlipidemia, hypertriglyceridemia and sitosterolemia. Bausch + Lomb confirms it is buying Novartis dry-eye treatment Xiidra from Novartes AG NVS, +0.90% NOVN in a deal valued at $2.5 billion. Shares of Chinook Therapeutics KDNY rose 67% to $40.02 after it agreed to be bought for up to $3.2 billion.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

This document will help you to evaluate Novartis AG without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, Ratings, company, value, Novartes, PCSK9, and the most common words in the summary are: novartis, university, chicago, market, party, night, stock, . One of the sentences in the summary was: Novartis AG has many opportunities for sustained growth in digital health, emerging markets, and gene therapy. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #university #chicago #market #party #night #stock.